50
Views
8
CrossRef citations to date
0
Altmetric
Research Article

The influence of combinations of oximes on the reactivating and therapeutic efficacy of antidotal treatment of soman poisoning in rats and mice

, , &
Pages 547-551 | Received 07 Aug 2009, Accepted 20 Sep 2009, Published online: 19 Oct 2009

References

  • Bajgar J. 2004. Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis and treatment. Adv Clin Chem 38:151–216.
  • Clement JG, Hansen AS, Boulet CA. 1992. Efficacy of HLö-7 and pyrimidoxime as antidotes of nerve agent poisoning in mice. Arch Toxicol 66:216–219.
  • Clement JG, Shiloff JD, Gennings Ch. 1987. Efficacy of a combination of acetylcholinesterase reactivators, HI-6 and obidoxime, against tabun and soman poisoning of mice. Arch Toxicol 61:70–75.
  • Dawson RM. 1994. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 14:317–331.
  • Ellman GL, Courtney DK, Andres V Jr, Feartherstone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–93.
  • Herkert NM, Lallement G, Clarencon D, Thiermann H, Worek F. 2009. Comparison of the oxime-induced reactivation of rhesus monkey, swine and guinea pig erythrocyte acetylcholinesterase following inhibition by sarin or paraoxon, using a perfusion model for the real-time determination of membrane-bound acetylcholinesterase activity. Toxicology 258:79–83.
  • Jeong HCH, Park N-J, Chae CHH, Musilek K, Kassa J, Kuca K, Jung Y-S. 2009. Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent. Bioorg Med Chem 17:6213–6217.
  • Jokanovic M, Prostran M. 2009. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem 16:2177–2188.
  • Jun D, Kuca K, Stodulka P, Koleckar V, Dolezal B, Simon P, Veverka M. 2007. HPLC analysis of HI-6 dichloride and dimethanesulfonate—antidotes against nerve agents and organophosphorus pesticides. Anal Lett 40:2783–2787.
  • Kassa J. 2002. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 40:803–816.
  • Kassa J, Karasova J, Musilek K, Kuca K. 2008a. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology 243:311–316.
  • Kassa J, Karasova J, Vasina L, Bajgar J, Kuca K, Musilek K. 2009a. A comparison of neuroprotective efficacy of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in tabun-poisoned rats. Drug Chem Toxicol 32:128–138.
  • Kassa J, Kuca K, Bartosova L, Kunesova G. 2007. The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr Org Chem 11:267–283.
  • Kassa J, Zdarova Karasova J, Musilek K, Kuca K. 2009b. A comparison of reactivating and therapeutic efficacy of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, HI-6) in cyclosarin-poisoned rats and mice. Toxicol Mech Meth 19:346–350.
  • Kassa J, Zdarova Karasova J, Pavlikova R, Misik J, Caisberger F, Bajgar J. 2009c. The influence of combinations of oximes on the reactivating and therapeutic efficacy of antidotal treatment of tabun poisoning in rats and mice. J Appl Toxicol DOI 10.1002/JAT.1477.
  • Kassa J, Zdarova Karasova J, Teserova S, Kuca K, Musilek K. 2008b. A comparison of the neuroprotective efficacy of newly developed oximes (K156, K203) and currently available oximes (obidoxime, HI-6) in cyclosarin-poisoned rats. Acta Med (Hradec Kralove) 51:215–221.
  • Kovacevic V, Maksimovic M, Deljac V, Binenfeld Z. 1991. Protective effects of mixture of oximes in poisoning by nerve chemical warfare agents. Acta Pharm Jugoslav 41:75–78.
  • Kovacevic V, Maksimovic M, Pantelic D, Vojvodic V, Binenfeld Z. 1989. Protective and reactivating effects of HI-6 PAM-2 mixture in rats poisoned with nerve chemical warfare agents. Acta Pharm Jugoslav 39:161–165.
  • Kovarik Z, Calic M, Sinko G, Bosak A, Berend S, Vrdoljak A, Radic B. 2008. Oximes: Reactivators of phsosphorylated acetylcholinesterase and antidotes in therapy against tabun poisoning. Chem-Biol Interact 175:173–179.
  • Kovarik Z, Lucic Vrdoljak A, Berend S, Catalinic M, Kuca K, Musilek K, Radic B. 2009. Evaluation of oxime K203 as antidote in tabun poisoning. Arh Hig Rada Toksikol 60:19–26.
  • Kuca K, Musilek K, Jun D, Pohanka M, Zdarova Karasova J, Novotny L, Musilova L. 2009. Could oxime HI-6 really be considered as ‘broad-spectrum’ antidote? J Appl Biomed 7:143–149.
  • Kuca K, Musilek K, Stodulka P, Marek J, Hanusova P, Jun D, Hrabinova M, Kassa J, Dolezal, B. 2007. Twelve different HI-6 salts and their potency to reactivate cyclosarin inhibited AChE in vitro. Lett Drug Des Discov 4:510–512.
  • Kuca K, Picha J, Cabal J, Liska F. 2004. Synthesis of the three monopyridinium oximes and evaluation of their potency to reactivate acetylcholinesterase inhibited by nerve agents. J Appl Biomed 2:51–56.
  • Lawrence DT, Kirk MA. 2007. Chemical terrorism attacks: update on antidotes. Emerg Med Clin N Am 25:567–595.
  • Lorke DE, Hasan MY, Nurulain SM, Kuca K, Schmitt A, Petroianu GA. 2009. Efficacy of two asymmetric bispyridinium oximes (K-27 and K-48) in rats exposed to diisopropylfluorophosphate: comparison with pralidoxime, obidoxime, trimedoxime, methoxime, and HI-6. Toxicol Mech Meth 19:327–333.
  • Lotti M. 2000. Organophosphorus compounds. In: Spencer PS, Schaumburg HH (Eds.), Experimental and clinical neurotoxicology. New York: Oxford University Press. pp. 898–925.
  • Lundy PM, Raveh L, Amitai G. 2006. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning. Toxicol Rev 25:231–243.
  • Luo CY, Tong M, Chilukuri N, Brecht K, Maxwell DM, Saxena A. 2007. An in vitro comparative study on the reactivation of nerve agent-inhibited guinea-pig and human acetylcholinesterases by oximes. Biochemistry 48:11771–11779.
  • Maksimovic M, Kovacevic V. 1989. Protective and reactivating effects of HI-6-toxogonin mixture in rats and guinea-pigs poisoned by nerve agents. Acta Pharm Jugoslav 39:27–33.
  • Marrs TC, Rice P, Vale JA. 2006. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 25:297–323.
  • Musilek K, Holas O, Kuca K, Jun D, Dohnal V, Opletalova V, Dolezal M. 2008. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited inhibited acetylcholinesterase. J Enzym Inhib Med Chem 23:70–76.
  • Musilek K, Kuca K, Jun D, Dolezal, M. 2006. Synthesis of bispyridinium compounds bearing propane linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. Lett Org Chem 3:831–835.
  • Musilek K, Kuca K, Jun D, Dolezal M. 2007. In vitro reactivation potency of bispyridinium (E)-but-2-ene linked acetylcholinesterase reactivators against tabun-inhibited acetylcholinesterase. J Appl Biomed 5:25–30.
  • Nurulain SM, Lorke DE, Hasan MY, Shafiullah M, Kuca K, Musilek K, Petroianu GA. 2009. Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime. Neurotox Res 16:60–67.
  • Szinicz L, Worek F, Thiermann H, Kehe K, Eckert S, Eyer P. 2007. Development of antidotes: problems and strategies. Toxicology 233:23–30.
  • Tallarida R, Murray R. 1987. Manual of pharmacological calculation with computer programs. New York: Springer-Verlag.
  • Worek F, Aurbek N, Thiermann H. 2007. Reactivation of organophosphate-inhibited human AChE by combinations of obidoxime and HI 6 in vitro. J Appl Toxicol 27:582–588.
  • Yanagisawa N, Morita H, Nakajima T. 2006. Sarin experience in Japan: acute toxicity and long-term effects. J Neurol Sci 249:76–85.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.